Guangzhou Wondfo Biotech Co.,Ltd
300482.SZ
Shenzhen Stock Exchange17.15
CNY
-0.08
- -
Guangzhou Wondfo Biotech Co.,Ltd
300482.SZ
(Shenzhen Stock Exchange)
Recent
price
17.15
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Guangzhou Wondfo Biotech Co., Ltd. (300482.SZ) develops, manufactures, and sells in vitro diagnostic (IVD) products, specializing in point-of-care testing (POCT) reagents, instruments, and chronic disease management solutions. The company offers rapid test kits for COVID-19, influenza (including Flu Series and H7 avian influenza antigen), drug of abuse, infectious diseases, tumors, fertility, sexually transmitted diseases, and maternal & child health; immunofluorescence analyzers and reagents such as FS-1000, FS-2000, and upgraded models for detecting cardiovascular diseases, inflammation, kidney injury, diabetes, renal functions, coagulation, thyroid hormones, rheumatoid arthritis, and respiratory issues; chemiluminescence platforms including the FC-2100 fully automated analyzer; molecular diagnostic systems for nucleic acid amplification in medium-throughput and POCT applications; blood coagulation, optical coagulation, thrombelastography, blood gas, hemoglobin, and automatic chemiluminescence immunoassay analyzers; fully automated pathology staining systems; and consumer diagnostics like WELLlife COVID-19/Flu A&B home tests, pregnancy tests, blood glucose, and cholesterol monitoring solutions. These products support clinical testing, critical illness diagnosis, primary care, epidemic monitoring, forensic applications, and family health management across segments including immunoassay, molecular diagnostics, electrochemistry, immune colloidal gold, immune-fluorescence, dry biochemistry, and pathology with AI integration. Founded in 1992 and headquartered in Guangzhou Science City, Huangpu District, China, the company employs over 3,000 people and distributes its offerings to approximately 150 countries and regions worldwide, with a focus on developing markets along the Belt and Road Initiative, small and mid-sized medical institutions, third-party labs, and hospital emergency settings. In 2024, Wondfo reported revenue of RMB 3.065 billion, up 10.85% year-over-year, with R&D investment of RMB 438 million (14.3% of revenue); it launched 82 new products (75 reagents and 7 devices), advanced IPD transformation across seven key disease areas (cardiovascular & metabolic, oncology, respiratory, infectious diseases, maternal & child health, drug testing, diabetes), gained FDA approval for its WELLlife home test, achieved recognition as China's leading brand in infectious disease rapid testing and top HIV/STD test brand, partnered with JD Health and others for diagnostic collaborations, progressed regulatory approvals for molecular tests, and announced plans for over $15 million investment in an Ethiopian manufacturing facility for African exports.